Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SOAT2 | O75908 | 1/20 | 0.52 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.51 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL30758614 | 0.98 | LMNA (0.97) | LMNAKMT2AGAAHTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL28857355 | 0.98 | LMNA (0.97) | LMNAKMT2AGAAHTTSMN1; SMN2 | |
| SCHEMBL24574897 | 0.92 | LMNA (0.85) | LMNAKMT2AGAAHTTSMN1; SMN2 | |
| SCHEMBL8460947 | 0.90 | LMNA (0.81) | LMNAKMT2AGAAHTTSMN1; SMN2 | |
| SCHEMBL14199811 | 0.89 | LMNA (0.80) | LMNAKMT2AGAAHTTSMN1; SMN2 | |
| SCHEMBL16203606 | 0.89 | KMT2A (0.79) | LMNAKMT2AGAAHTTSMN1; SMN2 | |
| SCHEMBL16203451 | 0.88 | LMNA (0.77) | LMNAKMT2AGAAHTTSMN1; SMN2 | |
| SCHEMBL16591365 | 0.85 | LMNA (0.74) | LMNAKMT2AGAAHTTSMN1; SMN2 | |
| SCHEMBL19138403 | 0.85 | KMT2A (0.73) | LMNAKMT2ASMN1; SMN2LPAR1 | |
| SCHEMBL16203502 | 0.84 | LMNA (0.71) | LMNAKMT2AGAAHTTKCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317917-A1 | METHODS FOR HYDROAMINOALKYLATION OF OLEFINS AND GROUP 4 METAL COMPLEXES USEFUL IN SUCH METHODS | UNIV BRITISH COLUMBIA (CA) | 2024-09-26 | — | — | US | disclosed |
| WO-2022133594-A1 | METHODS FOR HYDROAMINOALKYLATION OF OLEFINS AND GROUP 4 METAL COMPLEXES USEFUL IN SUCH METHODS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022133594-A1 | METHODS FOR HYDROAMINOALKYLATION OF OLEFINS AND GROUP 4 METAL COMPLEXES USEFUL IN SUCH METHODS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-30 | — | — | WO | disclosed |
| EP-3436488-B1 | AN OLEFIN POLYMERIZATION CATALYST | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-05-18 | — | — | EP | disclosed |
| CN-108779205-B | Olefin polymerization catalyst | 陶氏环球技术有限责任公司 | 2022-01-07 | — | — | CN | disclosed |
| US-10975172-B2 | Olefin polymerization catalyst | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200299420-A1 | OLEFIN POLYMERIZATION CATALYST | DOW GLOBAL TECHNOLOGIES LLC (US) | 2020-09-24 | — | — | US | disclosed |
| WO-2019199519-A1 | MIXED CATALYST SYSTEMS CONTAINING IRON TRIDENTATE CARBENES AND METHODS FOR MAKING POLYMER PRODUCTS USING SAME | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190308181-A1 | Mixed Catalyst Systems Containing Iron Tridentate Carbenes and Methods for Making Polymer Products Using Same | EXXONMOBIL CHEMICAL PATENTS INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3436488-A1 | AN OLEFIN POLYMERIZATION CATALYST | Dow Global Technologies, LLC (US) | 2019-02-06 | — | — | EP | disclosed |
| EP-1664132-A1 | POLYMERIZATION CATALYSTS, PREPARATION OF POLYOLEFINS, ORGANOTRANSITION METAL COMPOUNDS AND LIGANDS | Basell Polyolefine GmbH (DE) | 2006-06-07 | — | — | EP | disclosed |
| US-6969748-B2 | Metal complexes of iminohydroxamic acids | BASF AKTIENGESELLSCHAFT (DE) | 2005-11-29 | — | — | US | disclosed |
| US-20050085603-A1 | Metal complexes of iminohydroxamic acids | BASF AKIENGESELLSCHAFT (DE) | 2005-04-21 | — | — | US | disclosed |
| WO-2005030813-A1 | POLYMERIZATION CATALYSTS, PREPARATION OF POLYOLEFINS, ORGANOTRANSITION METAL COMPOUNDS AND LIGANDS | BASELL POLYOLEFINE GMBH (DE) | 2005-04-07 | — | — | WO | disclosed |
| US-6846771-B2 | Metal complexes of iminohydroxamic acids | BASF AKTIENGESELLSCHAFT (DE) | 2005-01-25 | — | — | US | disclosed |
| US-6828454-B2 | Refluxing N-(2,6-diisopropylphenyl)benzamide and dimethyl hydrazine or methylhydroxylamine, to form ligand, then complexing metal halides, to form polymerization catalysts | BASF AKTIENGESELLSCHAFT (DE) | 2004-12-07 | — | — | US | disclosed |
| US-20030195111-A1 | Metal complexes of iminohydroxamic acids | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-16 | — | — | US | disclosed |
| US-20030191255-A1 | Metal complexes of iminohydroxamic acids | BASF AKTIENGESELLSCHAFT (DE) | 2003-10-09 | — | — | US | disclosed |
| EP-1336613-A2 | Metal complexes with iminohydroxamic acid as a ligand | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-20 | — | — | EP | disclosed |
| EP-1336615-A2 | Metal complexes with iminohyrdoxamic acid as a ligand | BASF AKTIENGESELLSCHAFT (DE) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191255-A1 | Metal complexes of iminohydroxamic acids | ACOX1, ACAD9, NDUFAB1 | LMNA 1466/4885KMT2A 3063/4885GAA 2387/4885 |
| US-20050085603-A1 | Metal complexes of iminohydroxamic acids | ACAD9, INTS9, ETFA | LMNA 533/4885KMT2A 2704/4885GAA 2881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.